CG
VRTX icon

Carmignac Gestion’s Vertex Pharmaceuticals VRTX Stock Holding History

Carmignac Gestion’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81M Buy
163,045
+14,846
+10% +$6.58M 1.05% 24
2026
Q1 		$66.2M Sell
148,199
-43,372
-23% -$20.2M 1.02% 26
2025
Q4 		$86.9M Buy
191,571
+4,032
+2% +$1.74M 1.17% 22
2025
Q3 		$73.5M Sell
187,539
-39,757
-17% -$16.6M 1.09% 26
2025
Q2 		$101M Buy
227,296
+100,342
+79% +$46.2M 1.56% 22
2025
Q1 		$61.6M Sell
126,954
-70,512
-36% -$32.9M 1.01% 29
2024
Q4 		$79.5M Sell
197,466
-13,056
-6% -$6.05M 1.27% 27
2024
Q3 		$97.9M Buy
210,522
+25,273
+14% +$12.1M 1.63% 19
2024
Q2 		$86.8M Buy
+185,249
New +$80.4M 1.49% 20

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Carmignac Gestion's VRTX Position: Q2 2026 in Review

Carmignac Gestion increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, buying an estimated $6.58M and bringing the position to 163,045 shares worth $81M. The position accounts for 1.05% of the portfolio, ranked #24.

Carmignac Gestion first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $101M in Q2 2025. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Carmignac Gestion held 163,045 shares of Vertex Pharmaceuticals worth $81M as of Q2 2026.
  • Carmignac Gestion bought 14,846 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.58M.
  • Vertex Pharmaceuticals made up 1.05% of Carmignac Gestion's portfolio in Q2 2026, its #24 holding.
  • Carmignac Gestion first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Carmignac Gestion's Vertex Pharmaceuticals position peaked at $101M in Q2 2025.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Carmignac Gestion's 13F filing for Q2 2026, filed 13 Aug 2026.